Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxaliplatin
Drug ID BADD_D01633
Description Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.
Indications and Usage Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Marketing Status approved; investigational
ATC Code L01XA03
DrugBank ID DB00526
KEGG ID D01790
MeSH ID D000077150
PubChem ID 9887053
TTD Drug ID D0Y3ME
NDC Product Code 0703-3986; 13808-502; 0955-1733; 25021-233; 68083-171; 72603-101; 0955-1727; 57884-0017; 63592-0700; 50742-406; 55150-332; 67184-0501; 68083-170; 68083-176; 0955-1731; 72659-865; 43066-014; 68001-468; 71288-101; 82920-704; 16729-332; 45963-611; 67184-0502; 67184-0509; 0781-3317; 0781-9317; 67457-469; 0703-3985; 54875-0006; 67184-0510; 67457-442; 68083-314; 72266-126; 0781-3315; 50742-405; 71288-149; 72266-162; 0781-9315; 55150-331; 61703-363; 63323-750; 67184-0508; 72266-125; 72266-161; 72603-301; 79672-825; 0955-1725; 53104-7649; 67184-0007; 68554-0083; 60505-6132; 68083-177; 79672-826; 14778-0404; 49812-0075; 43066-018
UNII 04ZR38536J
Synonyms Oxaliplatin | Oxalato-(1,2-cyclohexanediamine)platinum II | Oxaliplatin, (SP-4-2-(1R-trans))-isomer | L-OHP Cpd | Platinum(II)-1,2-cyclohexanediamine Oxalate | 1,2-Diaminocyclohexane Platinum Oxalate | 1,2 Diaminocyclohexane Platinum Oxalate | 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) | Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) | Oxaliplatine | Eloxatine | Eloxatin | Oxaliplatin, (SP-4-3-(cis))-isomer | ACT 078 | ACT-078 | ACT078 | Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) | Oxaliplatin, (SP-4-2-(1S-trans))-isomer
Chemical Information
Molecular Formula C8H14N2O4Pt
CAS Registry Number 61825-94-3
SMILES C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.006167%
Abdominal pain upper07.01.05.0030.003212%
Acidosis14.01.03.0020.000280%
Acute hepatic failure09.01.03.0010.000280%Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.000392%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.000783%Not Available
Acute pulmonary oedema22.01.03.005; 02.05.02.0040.000224%Not Available
Acute respiratory distress syndrome24.03.02.034; 10.02.01.067; 22.01.03.0010.000728%
Acute respiratory failure22.02.06.001; 14.01.04.0040.001399%Not Available
Adenocarcinoma16.16.01.0040.000112%Not Available
Agitation19.06.02.001; 17.02.05.0120.001366%
Agranulocytosis01.02.03.0010.000392%Not Available
Alanine aminotransferase13.03.04.002--Not Available
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.000672%Not Available
Amaurosis fugax06.02.10.002; 24.04.06.006; 17.08.04.0020.000336%Not Available
Anaemia01.03.02.0010.003190%
Anaphylactic reaction24.06.03.006; 10.01.07.0010.004209%
Anaphylactic shock24.06.02.004; 10.01.07.0020.003526%Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.0030.000951%Not Available
Anger19.04.02.001--Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.000560%
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anuria20.01.03.0020.000280%Not Available
Anxiety19.06.02.002--
Aphasia19.21.01.001; 17.02.03.0010.001690%
Aphonia22.12.03.001; 17.02.08.009; 19.19.01.0020.000694%
Aphthous ulcer07.05.06.0020.000168%Not Available
Aplasia pure red cell10.02.01.003; 01.03.03.0010.000280%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene